News

Basel, Switzerland, February 23, 2018   Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has commenced enrollment in the first of its two planned clinical phase 3 registration studies of the antibiotic ceftobiprole. The first study evaluates the safety and efficacy of the antibiotic in the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Basilea expects to begin enrollment in the second phase 3 clinical trial of ceftobiprole in the treatment of adult patients with bacteremia (bloodstream infection) caused by Staphylococcus aureus mid-2018. The two trials are designed to be cross-supportive for a potential U.S. registration and are conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

Basel, Switzerland, February 21, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea's Board of Directors has appointed David Veitch, currently Basilea's Chief Commercial Officer and member of the Management Committee, to succeed Mr. Scott in the role of Chief Executive Officer effective April 19, 2018.

Basel, Switzerland, January 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the completion of its extension of its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba® (isavuconazole) to include China (with Hong Kong and Macao) and sixteen countries in the Asia Pacific region, execution of which was announced on December 1, 2017. The amendment was subject to customary regulatory review which has completed. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections.

Basel, Switzerland, January 03, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the initiation of a phase 1 study conducted under its clinical study agreement with the Adult Brain Tumor Consortium (ABTC) in the U.S. The first patient has been treated in this open-label dose-escalation study to determine the safety and tolerability of the oral formulation of Basilea's novel anticancer drug candidate BAL101553 in combination with standard radiation in patients with newly-diagnosed glioblastoma. Patients participating in the study have a reduced sensitivity to standard chemotherapy with temozolomide due to an unmethylated MGMT promoter.

Basel, Switzerland, December 21, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product (QIDP). The designation relates to the potential use of the drug in the treatment of bacterial bloodstream infections (bacteremia) caused by Staphylococcus aureus.

Basel, Switzerland, October 31, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea's Head of Development, to succeed Prof. Kaufhold in the role of Chief Medical Officer and as a member of the Management Committee effective January 1, 2018.

Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) in the United States exceeded the threshold triggering the first sales milestone payment from Astellas Pharma Inc. ("Astellas") to Basilea in the amount of CHF 5 million.